Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 27,098 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 27,098 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $30.08, for a total transaction of $815,107.84. Following the transaction, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $839,773.44. This represents a 49.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $30.89 on Monday. The stock has a market cap of $6.75 billion, a P/E ratio of 70.20 and a beta of 1.31. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02. The firm’s fifty day moving average price is $28.22 and its 200-day moving average price is $22.19.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. The company’s revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) EPS. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on HIMS shares. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their target price for the company from $24.00 to $25.00 in a research note on Friday, January 10th. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Piper Sandler lifted their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently made changes to their positions in the stock. Raleigh Capital Management Inc. grew its position in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares in the last quarter. Quest Partners LLC increased its position in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 115.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after buying an additional 2,442 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.